Session Information
Date: Tuesday, November 10, 2026
Session Type: Abstract Session
Session Time: 2:15PM-2:30PM
Background/Purpose:
Systemic autoimmune rheumatic diseases (SARDs) cause significant morbidity and mortality through diverse mechanisms. Major implicated drivers include interferon (IFN), T cell, inflammasome/IL-6, and TNF-α signaling. Interstitial lung disease (ILD) is a major comorbidity of SARDs, including rheumatoid arthritis (RA), myositis, and systemic sclerosis (SSc). However, plasma cytokine profiles have not been systematically compared across SARD-ILD states. We hypothesized that cytokine profiles would differ across SARDs, associate with ILD status in a SARD-specific manner, and reveal distinct interferon-associated signatures among myositis subtypes.
Methods:
Plasma was collected 2011-2025 from 125 patients. Patients carried diagnoses of RA (n=30, 15 ILD), SSc (n=35,19), MDA5-myositis (n=19, 9), Jo-1-myositis (n=31, 16), and healthy controls (HC, n=10). ILD status was assessed by chart review. Cytokines were selected from mRNA sequencing data implicating IFN signaling in ILD. Plasma CXCL9, CXCL10, IL-18, IL-2Rα, and TNF-α were measured by Ella automated immunoassay (Bio-Techne). Log-transformed cytokine levels were analyzed using rank-based regression models incorporating disease, ILD status, and disease × ILD status interaction terms, with FDR multiple comparison correction. A separate FDR-corrected model compared each disease to HC. Per-patient CXCL9/CXCL10 ratios were compared between myositis subtypes and by ILD status.
Results:
Disease × ILD interactions were seen for CXCL9, CXCL10, IL-2Rα, and TNF-α (Fig 1a). Specifically in RA, ILD was associated with significantly higher levels of these cytokines (Fig 1b). Within other SARDs, no comparable ILD-associated elevations were observed, indicating this is specific to RA. Additionally, TNF-α was lower in MDA5 patients with ILD than in those without (Fig 1b).
Notably, CXCL9 and CXCL10 were elevated in non-RA SARDs regardless of ILD status, reflecting SARD- rather than ILD-driven elevation. Among SARDs, median CXCL9 was highest in Jo-1 and CXCL10 in MDA5 myositis, respectively. Correspondingly, in Jo-1, CXCL9/10 ratios showed a ~3.2-fold increase in CXCL9 over CXCL10, while in MDA5, the levels of CXCL9 and CXCL10 were approximately balanced, both independent of ILD status (Fig 2). Of all disease groups, IL-18 was elevated relative to HC in only MDA5 (p_adj=0.037).
Conclusion:
Plasma cytokine profiles differed across SARDs, and ILD-associated elevation was specific to RA. Jo-1 and MDA5 exhibited contrasting CXCL9/CXCL10 ratios, consistent with previously reported type II vs. type I interferon pathway induction, while elevated IL-18 in MDA5 suggesting macrophage activation. These findings reveal disease-specific inflammatory signatures and identify an RA-specific association between ILD status and cytokine levels that may provide insight into disease biology with potential diagnostic implications.
Figure 1. Plasma cytokines by disease and ILD status. Drop-in-dispersion p per model term, FDR-adjusted (A). Cytokine by disease and ILD status, ILD effects obtained by refitting the model with each disease as reference, FDR-adjusted (B). *p<0.05, **p<0.01, ***p<0.001
Figure 2. Per-patient log10(CXCL9/CXCL10), Jo-1 (n=31) and MDA5 (n=19); dash=balanced expression, positive=CXCL9 dominance, negative=CXCL10 dominance (p<0.001; Cliff's δ=0.78).
To cite this abstract in AMA style:
Pfuhler L, Zenati M, Watson C, Chiang S, Cobb C, Ascherman D, Schwartz D. Distinct Plasma Cytokine Profiles Across Rheumatic Diseases Reveal an RA-Specific Interstitial Lung Disease Signature [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/distinct-plasma-cytokine-profiles-across-rheumatic-diseases-reveal-an-ra-specific-interstitial-lung-disease-signature/. Accessed .ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinct-plasma-cytokine-profiles-across-rheumatic-diseases-reveal-an-ra-specific-interstitial-lung-disease-signature/
